The disclosure provides compositions comprising peptide-based nanofiber precursors and methods of using the same to inhibit cancerous cell growth and/or to deliver therapeutic or diagnostic agents to cells, e.g., cancerous cells. The compositions of the present technology include peptide-based nanofiber precursors as well as carrier complexes comprising a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor. Also provided herein are methods for delivering a therapeutic or diagnostic agent to a cell comprising contacting the cell with a carrier complex including a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.

A material for treatment of brain injury, a method for treatment of brain injury, a material for regeneration of brain neurons, and a method for regeneration of brain neurons are provided. The material for treatment of brain injury contains a carrier on which at least one selected from the group consisting of N-cadherin, a fusion protein containing an entire or partial region of N-cadherin, and a fusion protein containing an entire or partial region of a protein having homology to N-cadherin is immobilized or coated.

Polymeric drugs for disease therapy are provided. The repeat units of the polymers comprise at least one chemotherapeutic agent, e.g. a cancer drug. The linkages between repeat units are hydrolysable under physiological conditions, e.g. at targeted sites in vivo. Nanoparticles formed from the polymers are also provided.

A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.

Disclosed is a method of preparing a medical preparation with a carrier based on hyaluronan and/or its derivatives, which can be used in the field of medicine and cosmetics. The medical preparation comprises a conjugate of hyaluronic acid and/or its derivative with a medical substance, according to the general formula A-SN, where: A is the medical substance; S is the way of linking the medical substance with the carrier; and N is the carrier based on hyaluronic acid and/or its derivatives.

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

A complex includes an amyloid peptide complexed with a cholinesterase inhibitor, an NMDA receptor antagonist, or a combination, of a cholinesterase inhibitor and an NMDA receptor antagonist, wherein the amyloid peptide comprises X.sub.1X.sub.2GAIIGX.sub.3X.sub.4 (SEQ ID NO: 2), wherein X.sub.1 and X.sub.4 are each independently YF or FY, and X.sub.2 and X.sub.3 are each 1 amino acid long, and are each independently T, N, S, or Q; or X.sub.2 and X.sub.3 are each 2 amino acid long and X.sub.2 is (Y or F)T, (Y or F)N, (Y or F)S or (Y or F)Q, and X.sub.3 is T(Y or F), N(Y or F), S(Y or F) or Q(Y or F), wherein the amyloid peptide self-assembles into amyloid fibrils, and wherein the peptide has a total length of 11-13 amino acids.